益佰制药：小儿止咳糖浆恢复生产销售

Core Viewpoint - The company has resumed the production and sales of its pediatric cough syrup after receiving a notice of suspension from the Guizhou Provincial Drug Administration, which was lifted following corrective actions taken by the company [1] Financial Performance - Revenue from the pediatric cough syrup for the years 2021 to 2024 was recorded at 3.42 million, 4.32 million, 8.38 million, and 1.51 million respectively [1] - The revenue from this product represents a small proportion of the company's total consolidated revenue during the same periods, indicating that the impact of the resumption on overall performance is expected to be minimal [1]